Janssen India, the pharmaceutical division of Johnson & Johnson Private Limited, is proud to announce that the Company has been honored with CSR Health Impact’s prestigious Swasth Bharat award in recognition of its comprehensive and transformative work to support India’s efforts to address the growing challenge of multidrug-resistant tuberculosis (MDR-TB).
We are pleased with the conclusion of the Rajasthan FDA, which confirms that Johnson’s Baby Shampoo does not contain formaldehyde. This outcome reaffirms our own testing and the longstanding assurance we have that Johnson’s Baby Shampoo does not contain formaldehyde or any formaldehyde-releasing ingredients. Importantly, this is the result of the appellate laboratory, following a magistrate court order for re-testing, and overrules an earlier test result that was erroneous. Nothing is more important to us than the safety of the people who use our products, and our quality assurance process is rigorous – meeting or exceeding standards in every country where our products are sold.
India accounts for more than a quarter of the global burden of tuberculosis (TB), and for this reason is often called the TB capital of the world. 1 In a recent report titled, India Health of Nation’s States, TB was listed as one of the top ten causes of death in the country. 2 In recent years, the rapid emergence of multidrug-resistant TB (MDR-TB) – which does not respond to at least two of the most commonly used TB treatments – has made the situation worse.
Johnson & Johnson India has announced a strategic partnership with the Government of Maharashtra to implement focused disease interventions that have the potential to significantly improve the health of people and strengthen health care in the state.